AI Algorithm Can ID Metabolic Dysfunction-Associated Steatotic Liver Disease
By Lori Solomon HealthDay Reporter
WEDNESDAY, Nov. 27, 2024 -- An algorithm can identify individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) with about 88 percent accuracy using electronic medical record (EMR) data, according to a study presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, held from Nov. 15 to 19 in San Diego.
Ariana Stuart, M.D., from the University of Washington in Seattle, and colleagues described the development of an EMR-based artificial intelligence (AI) algorithm for MASLD identification.
The researchers reported that an iterative natural language processing pattern-recognition AI algorithm achieved about 88 percent accuracy versus manual MASLD diagnosis. Among 957 individuals identified by the algorithm as meeting criteria for MASLD, 56 percent were female, 2 percent American Indian/Native Alaskan, 6 percent Black/African American, 16 percent Asian, 68 percent White, and 12.2 percent Hispanic/Latino(a). More than one-fourth of patients (25.6 percent) had gastrointestinal or hepatology referral, but only 140 had an MASLD-associated diagnostic code. More than seven in 10 individuals (697) were identified as meeting criteria for MASLD diagnosis but did not already carry an MASLD diagnosis.
"People should not interpret our findings as a lack of primary care training or management," Stuart said in a statement. "Instead, our study shows how AI can complement physician workflow to address the limitations of traditional clinical practice."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted November 2024
Read this next
Dapagliflozin Beneficial for Improving MASH Without Worsening Fibrosis
FRIDAY, June 6, 2025 -- For patients with metabolic dysfunction-associated steatohepatitis (MASH), treatment with dapagliflozin is beneficial for improvement of MASH without...
Metabolic Dysfunction-Linked Steatotic Liver Disease Tied to Increased Preterm Birth Risk
TUESDAY, May 20, 2025 -- Metabolic dysfunction-associated steatotic liver disease (MASLD) in pregnant women is a risk factor for preterm birth, according to a study published...
Study IDs Trends in 2015 to 2023 Mortality for Chronic Liver Disease
THURSDAY, May 8, 2025 -- Distinct trends were seen in etiology-based mortality with chronic liver disease (CLD) before, during, and after the COVID-19 pandemic, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.